Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Cancers with kinase fusion exhibit fewer actionable alterations than those with kinase mutation and amplification

View through CrossRef
Abstract Background Kinase-related gene fusion and point mutations are important drivers, and optimized targeted therapy against these alterations is required. The effects of molecularly targeted therapeutics vary depending on the alteration, and such therapeutics have achieved their greatest success when used to treat chronic myelogenous leukemia with kinase fusion protein. In this study, we aimed to compare the numbers of actionable alterations in patients with kinase domain fusions, mutations, and amplifications. Methods To detect gene-fusion events, we analyzed 456 patients with 31 solid cancer types who visited our division between June 2020 and May 2023. We performed comprehensive genomic sequencing using FoundationOne® CDx (F1CDx) and FoundationOne® Liquid CDx (F1LCDx) to detect alterations involving multiple-fusion calling, and compared the number of actionable alterations in patients with kinase-domain fusions and mutations. The significance of these gene alterations was analyzed at a team conference. Results Among the 418 patients, we identified 44 with kinase-domain fusions, and F1CDx and F1LCDx detected 12 with kinase-domain fusions. We identified 78 patients with kinase-domain mutations and 33 with amplifications. The numbers of actionable alterations in patients with kinase-domain fusion, mutation, or amplification (median [IQR]) were 2 (0–3.5), 5 (4–7), and 5.5 (4.25–7.5), respectively. Patients with kinase fusion had significantly fewer actionable alterations than those with kinase-domain mutations and amplifications. However, those cancers with fusion involving tumor suppressors tended to have more passenger alterations (4 [2–9.75]; median [IQR]). Conclusions Cancers with kinase fusions tended to exhibit fewer actionable alterations than those with kinase mutations and amplifications. These findings indicate that kinase fusions are strong drivers of cancer development. In particular, kinase fusions in cancer are considered ideal targets for molecular therapeutics.
Title: Cancers with kinase fusion exhibit fewer actionable alterations than those with kinase mutation and amplification
Description:
Abstract Background Kinase-related gene fusion and point mutations are important drivers, and optimized targeted therapy against these alterations is required.
The effects of molecularly targeted therapeutics vary depending on the alteration, and such therapeutics have achieved their greatest success when used to treat chronic myelogenous leukemia with kinase fusion protein.
In this study, we aimed to compare the numbers of actionable alterations in patients with kinase domain fusions, mutations, and amplifications.
Methods To detect gene-fusion events, we analyzed 456 patients with 31 solid cancer types who visited our division between June 2020 and May 2023.
We performed comprehensive genomic sequencing using FoundationOne® CDx (F1CDx) and FoundationOne® Liquid CDx (F1LCDx) to detect alterations involving multiple-fusion calling, and compared the number of actionable alterations in patients with kinase-domain fusions and mutations.
The significance of these gene alterations was analyzed at a team conference.
Results Among the 418 patients, we identified 44 with kinase-domain fusions, and F1CDx and F1LCDx detected 12 with kinase-domain fusions.
We identified 78 patients with kinase-domain mutations and 33 with amplifications.
The numbers of actionable alterations in patients with kinase-domain fusion, mutation, or amplification (median [IQR]) were 2 (0–3.
5), 5 (4–7), and 5.
5 (4.
25–7.
5), respectively.
Patients with kinase fusion had significantly fewer actionable alterations than those with kinase-domain mutations and amplifications.
However, those cancers with fusion involving tumor suppressors tended to have more passenger alterations (4 [2–9.
75]; median [IQR]).
Conclusions Cancers with kinase fusions tended to exhibit fewer actionable alterations than those with kinase mutations and amplifications.
These findings indicate that kinase fusions are strong drivers of cancer development.
In particular, kinase fusions in cancer are considered ideal targets for molecular therapeutics.

Related Results

Comparison of actionable alterations in cancers with kinase fusion, mutation, and amplification
Comparison of actionable alterations in cancers with kinase fusion, mutation, and amplification
Abstract Kinase-related gene fusion and point mutations play pivotal roles as drivers in cancer, necessitating optimized targeted therapy against...
The Nuclear Fusion Award
The Nuclear Fusion Award
The Nuclear Fusion Award ceremony for 2009 and 2010 award winners was held during the 23rd IAEA Fusion Energy Conference in Daejeon. This time, both 2009 and 2010 award winners w...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Phosphatidylinositol 3′-kinase associates with an insulin receptor substrate-1 serine kinase distinct from its intrinsic serine kinase
Phosphatidylinositol 3′-kinase associates with an insulin receptor substrate-1 serine kinase distinct from its intrinsic serine kinase
Serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been proposed as a counter-regulatory mechanism in insulin and cytokine signalling. Here we report that IRS-1 is ...
Abstract 5171: Development of preclinical models of NTRK fusion-driven cancers
Abstract 5171: Development of preclinical models of NTRK fusion-driven cancers
Abstract Introduction: Oncogenic fusions involving the neurotrophic receptor tyrosine kinase genes, NTRK1, NTRK2, or NTRK3 are d...
Comparison of TP53 Alterations in Hematological Malignancies
Comparison of TP53 Alterations in Hematological Malignancies
Abstract Background: TP53 is altered in ~50% of human cancers. Alterations include mutations and deletions. Both frequently occur together, supportin...
Nonproliferation and fusion power plants
Nonproliferation and fusion power plants
Abstract The world now appears to be on the brink of realizing commercial fusion. As fusion energy progresses towards near-term commercial deployment, the question arises a...
The Diverse Landscape of Fusion Transcripts in 25 Different Hematological Entities
The Diverse Landscape of Fusion Transcripts in 25 Different Hematological Entities
Background: Genomic alterations are a hallmark of hematological malignancies and comprise small nucleotide variants, copy number alterations and structural variants (SV). SV lead t...

Back to Top